

# Evofem to Address the Cavendish Global Health Impact Forum at Biocom on Innovations in Reproductive Health Care around the globe.

SAN DIEGO – June 15, 2016 — Evofem, a biotechnology company focused on the development and commercialization of women's health products, announced today it has been selected to present at the upcoming Cavendish Global Health Impact Forum co-hosted with Biocom, June 20-23, 2016, in San Diego.

Cavendish Global Forums assist family offices and foundations in developing and implementing their individual pro-social impact investing, grant-giving and philanthropy programs within health and the life sciences. In accomplishing this, the Forums showcase presentations and panel discussions by leading family offices, foundations, research institutions and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of family offices, Cavendish Impact Forums are hosted by leading institutions around the world and take place three times each year.

The theme of the upcoming Forum is Innovation, Philanthropy and Investing Inspired for Impact. As one of the companies selected to participate and present at this year's Forum in San Diego, Sandra Pelletier, CEO of WomanCare Global and Evofem will present the unique innovations being developed by Evofem and WomanCare Global to meet the contraceptive needs of women across the globe. "Our team is working diligently to develop innovative treatments to meet the unmet reproductive health care needs of women," said Sandra Pelletier, Chief Executive Officer of Evofem. "There are approximately 225 million women who have a need for modern contraception globally. We look forward to meeting with accomplished entrepreneurs, thought-leaders and philanthropists who echo our mission addressing unintended pregnancy and gender inequality around the world."

## **About Evofem**

Evofem Holdings, Inc. seeks to address a growing global contraceptive market, while delivering effective, woman-controlled products with global distribution. Evofem has two lead product candidates: Amphora®, a vaginal contraceptive gel, and the Nestorone® Ring, a one-year contraceptive vaginal ring, both of which have completed Phase III clinical studies. For more information on the Company, visit [www.evofem.com](http://www.evofem.com).

## **About Cavendish Global**

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship-building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year. For more information: <http://cavendishglobal.com>

## **Media Inquiries**

Russell Barrans

[rbarrans@evofem.com](mailto:rbarrans@evofem.com)

(858) 550-1900, ext. 241

---